![\"EBU](\"https:\/\/www.pharmabraille.com\/wp-content\/uploads\/2015\/01\/braille-code.jpg\")
<\/p>\nRoyal National Institute of Blind People (RNIB) and the European Blind Union (EBU), who previously hosted this information, have helped us develop the European Braille Guidance area of our website to continue to provide access to the EBU recommended Braille code and practical guidance for implementing Pharmaceutical Braille in Europe.<\/p>\n
RNIB will continue to work with PharmaBraille to keep this information updated and provide Braille expertise and links with European sight loss organisations.<\/p>\n
<\/p>\n
From the end of October 2005, it became mandatory for all new pharmaceutical products for human use to be provided with Braille information on the packaging. Both regulatory and political authorities have encouraged Braille to be incorporated into all pharmaceutical products as rapidly as possible.<\/p>\n
We appreciate the complexities of Braille across the European market and understand that pharmaceutical companies and packaging organisations would like to be able to use the same Braille code across a European market.<\/p>\n
The EBU<\/a>\u00a0and RNIB<\/a>\u00a0has worked with many sight loss organisations to endeavour to provide an agreed Braille code and set of principles that can be used in many European countries. There is no intention to impose this on any European country and each Braille authority has the right to elect to allow the use of this code in their country or to require that the national Braille code is used.<\/p>\n This area of the website provides details of the Braille code that has been agreed between many European blindness organisations –\u00a0 the EBU Recommended Braille Code for Use on Pharmaceutical Packaging<\/a>. It also gives the\u00a0 EBU recommendations<\/a> answering many\u00a0frequently asked questions<\/a> about how the Braille code should be implemented such as, spacing, abbreviations, capitalisation and fitting Braille on the pack.<\/p>\n Details are also given relating to which countries have agreed to allow the use of this EBU code on pharmaceutical packaging.<\/p>\n Please note the EBU has no authority to enforce this code in any EU country although Braille authorities are encouraged to accept the use of this code on Pharmaceutical packaging used in their country. For a list of which countries accept the EBU recommended code please see\u00a0Summary of Acceptance<\/a>.<\/p>\n Duxbury Systems<\/a><\/strong>\u00a0leads the world in software for braille. The Duxbury Braille Translator (DBT) supports grade 1 and grade 2 translation in English, Spanish, French, German, Portuguese, Arabic, Malaysian, Swedish, and other languages.<\/p>\n RNIB<\/strong><\/a>\u00a0provide support and guidance for all aspects of braille production and use.<\/p>\n MHRA<\/strong><\/a>, the UK medicines regulators, provide pharmaceutical braille information for labelling and patient information leaflets.<\/p>\n Perkins Braille<\/strong><\/a>\u00a0publish World Braille Usage<\/a>\u00a0\u2014 the most comprehensive reference to international braille codes.<\/p>\n\nOther Sources of Pharmaceutical Braille Guidance, Software and Tools<\/h2>\n